Business Description
Biosergen AB
ISIN : SE0016013460
Compare
Compare
Traded in other countries / regions
BIOSGN.Sweden8N1.Germany IPO Date
2021-06-24Description
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.29 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -30.1 | |||||
| 3-Year EPS without NRI Growth Rate | -26.9 | |||||
| 3-Year FCF Growth Rate | -54 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.37 | |||||
| 9-Day RSI | 44.8 | |||||
| 14-Day RSI | 44.01 | |||||
| 6-1 Month Momentum % | -45.45 | |||||
| 12-1 Month Momentum % | -43.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.42 | |||||
| Quick Ratio | 1.42 | |||||
| Cash Ratio | 0.37 | |||||
| Days Payable | 3405.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -228.34 | |||||
| ROA % | -141.97 | |||||
| ROIC % | -465.13 | |||||
| ROC (Joel Greenblatt) % | -2749.54 | |||||
| ROCE % | -228.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 12.36 | |||||
| Price-to-Tangible-Book | 10.3 | |||||
| EV-to-EBIT | -1.56 | |||||
| EV-to-Forward-EBIT | -1.89 | |||||
| EV-to-EBITDA | -1.56 | |||||
| EV-to-FCF | -1.29 | |||||
| Price-to-Net-Current-Asset-Value | 15.45 | |||||
| Earnings Yield (Greenblatt) % | -64.1 | |||||
| FCF Yield % | -74.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biosergen AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.337 | ||
| Beta | 0 | ||
| Volatility % | 97.37 | ||
| 14-Day RSI | 44.01 | ||
| 14-Day ATR (kr) | 0.027243 | ||
| 20-Day SMA (kr) | 0.31695 | ||
| 12-1 Month Momentum % | -43.08 | ||
| 52-Week Range (kr) | 0.224671 - 1.176569 | ||
| Shares Outstanding (Mil) | 142.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biosergen AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biosergen AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biosergen AB Frequently Asked Questions
What is Biosergen AB(OSTO:BIOSGN)'s stock price today?
The current price of OSTO:BIOSGN is kr0.31. The 52 week high of OSTO:BIOSGN is kr1.18 and 52 week low is kr0.22.
When is next earnings date of Biosergen AB(OSTO:BIOSGN)?
The next earnings date of Biosergen AB(OSTO:BIOSGN) is 2024-05-31.
Does Biosergen AB(OSTO:BIOSGN) pay dividends? If so, how much?
Biosergen AB(OSTO:BIOSGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers